PerkinElmer, Inc.
PKI
|
$115.24
0.0%
1.6M
|
Health Technology
(0.0% 1d) (-1.7% 1m) (-12.8% 1y) (-1.7% 2d) (-8.0% 3d) (0.0% 7d) (-51.16% volume)
Earnings Calendar: 2023-08-01
Market Cap: $ 14,455,821,070
http://www.perkinelmer.com
Sec Filling | Patents | 13000 employees
(US) PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.
food diagnostics treatment
add to watch list Paper trade email alert is off
Ayala Pharmaceuticals, Inc.
AYLA
|
$0.5036
5.84%
-0.7%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.
cancer israel diagnostics
add to watch list Paper trade email alert is off
Heska Corporation
HSKA
|
$119.99
0.0%
390K
|
Health Technology
(0.0% 1d) (0.0% 1m) (2.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (87.26% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,309,541,342
http://www.heska.com
Sec Filling | Patents | 386 employees
(US) Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through two segments: Core Companion Animal Health and Other Vaccines & Pharmaceuticals. The Core Companion Animal Health segment includes point of care diagnostic laboratory instruments and supplies, imaging instruments, software, and services as well as single use diagnostic and other tests, pharmaceuticals, and vaccines. The Other Vaccines & Pharmaceuticals segment focuses on private label vaccine and pharmaceutical production, primarily for cattle, but also for equine, porcine, avian, feline, and canine. Heska was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.
vaccine animals diagnostics veterinary
add to watch list Paper trade email alert is off
Forward Pharma A/S
FWP
|
$1.95
7.74%
7.18%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-64.55% volume)
Earnings Calendar:
Market Cap: $ 13,827,811
http://www.forward-pharma.com
Sec Filling | Patents | 5 employees
(DK) Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.
neurological treatment
add to watch list Paper trade email alert is off
Genocea Biosciences, Inc.
GNCA
|
$0.051
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees
(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
vaccine cancer immunotherapy t-cell genetic treatment ceiling
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
ABIOMED, Inc.
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (758.37% volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec Filling | Patents | 1536 employees
(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
heart brands
add to watch list Paper trade email alert is off
Acer Therapeutics Inc.
ACER
|
$0.9
-3.61%
420K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-12.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1077.06% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 22,017,353
http://www.acertx.com
Sec Filling | Patents | 17 employees
(US) Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.
acquisitions urine urea treatment
add to watch list Paper trade email alert is off
Adamis Pharmaceuticals Corporation
ADMP
|
$0.7751
0.86%
2.6%
120K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-88.5% 1y) (0.0% 2d) (0.9% 3d) (0.0% 7d) (20.14% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 7,254,264
http://www.adamispharmaceuticals.com
Sec Filling | Patents | 171 employees
(US) Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.
respiratory opioid
add to watch list Paper trade email alert is off
Aerie Pharmaceuticals, Inc.
AERI
|
$15.25
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees
(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
eye treatment
Drugs
Rhopressa (netarsudil)Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)
add to watch list Paper trade email alert is off
Midatech Pharma PLC
MTP
|
$0.4703
-70.79%
-73.69%
0
|
Health Technology
(0.0% 1d) (-11.4% 1m) (0.0% 1y) (-11.4% 2d) (-11.4% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 3,260,999
http://midatechpharma.com/
Sec Filling | Patents | n/a employees
Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programmes. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is a innovative nanosaccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is a edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale ie i. chemotherapy - improved and targeted delivery of existing chemotherapeutic agents to tumor sites, as well as ii. immunotherapy - enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
cancer immunotherapy t-cell drug delivery housing ceiling
add to watch list Paper trade email alert is off
Mirati Therapeutics, Inc.
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (43.1% 1y) (0.0% 2d) (-0.1% 3d) (0.0% 7d) (-41.54% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 4,117,670,342
http://www.mirati.com
Sec Filling | Patents | 111 employees
(US) Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
cancer immunology genetic
add to watch list Paper trade email alert is off
Neptune Wellness Solutions Inc.
NEPT
4
|
$0.2
-4.95%
2.3M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-69.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2536.95% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 906,408
http://neptunecorp.com
Sec Filling | Patents | 165 employees
(CA) Neptune Wellness Solutions, Inc. is a diversified health and wellness company. It engages in building a broad portfolio of quality, affordable consumer products in response to long-term secular trends and market demand for natural, plant-based, sustainable and purpose-driven lifestyle brands. The company utilizes a flexible, cost efficient manufacturing and supply chain infrastructure that can be scaled up and down or into adjacent product categories to identify opportunities, quickly adapt to consumer preferences and demand, and bring new products to market through its mass retail partners and e-commerce channels. Neptune Wellness Solutions was founded by Henri Harland on October 9, 1998 and is headquartered in Laval, Canada.
brands
add to watch list Paper trade email alert is off
IMV Inc.
IMV
|
$0.8225
-2.74%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (22.8% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.
vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling
add to watch list Paper trade email alert is off
La Jolla Pharmaceutical Company
LJPC
|
$6.22
0.0%
|
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (0.0% 2d) (0.8% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 155,107,412
http://www.lajollapharmaceutical.com
Sec Filling | Patents | 91 employees
(US) La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
hormone msa treatment
Drugs
Giapreza (angiotensin II)add to watch list Paper trade email alert is off
Satsuma Pharmaceuticals, Inc.
STSA
|
$1.1
-0.9%
-0.91%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (7.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (445.43% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 36,467,748
http://www.satsumarx.com
Sec Filling | Patents | 17 employees
(US) Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
migraine treatment
add to watch list Paper trade email alert is off
Second Sight Medical Products, Inc.
EYES
|
$4.14
-0.24%
3.14%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap:
http://www.secondsight.com
Sec Filling | Patents | 112 employees
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
china prosthetics
add to watch list Paper trade email alert is off
Selecta Biosciences, Inc.
SELB
4
|
$0.8812
-8.0%
2.12%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-23.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 136,765,573
http://www.selectabio.com
Sec Filling | Patents | 39 employees
(US) Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
vaccine gene therapies msa treatment pompe disease
add to watch list Paper trade email alert is off
Tricida, Inc.
TCDA
|
$0.108
-22.22%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-44.76% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 6,012,239
http://www.tricida.com
Sec Filling | Patents | 119 employees
(US) Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.
kidney diseases metabolic kidney
add to watch list Paper trade email alert is off
Turning Point Therapeutics, Inc.
TPTX
|
$76.01
-0.03%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,806,145,795
http://www.tptherapeutics.com
Sec Filling | Patents | 95 employees
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
cancer
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10